Page 7 - Read Online
P. 7
Cancer Drug Resistance
CONTENTS
Topic: Targeting DNA Topoisomerases - Past and Future
1 Targeting DNA topoisomerases: past & future
William H. Gmeiner, Robert C. A. M. van Waardenburg
Cancer Drug Resist 2021;4:758-761 https://dx.doi.org/10.20517/cdr.2021.65
2 Entrapment of DNA topoisomerase-DNA complexes by nucleotide/nucleoside analogs
William H. Gmeiner
Cancer Drug Resist 2019;2:994-1001 http://dx.doi.org/10.20517/cdr.2019.95
3 Targeting Tyrosyl-DNA phosphodiesterase I to enhance toxicity of phosphodiester linked
DNAadducts
Evan J. Brettrager, Robert C.A.M. van Waardenburg
Cancer Drug Resist 2019;2:1153-1163 http://dx.doi.org/10.20517/cdr.2019.91
4 Topoisomerase IB: a relaxing enzyme for stressed DNA
Bini Chhetri Soren, Jagadish Babu Dasari, Alessio Ottaviani, Federico Iacovelli, Paola Fiorani
Cancer Drug Resist 2020;3:18-25 http://dx.doi.org/10.20517/cdr.2019.106
5 The interplay between DNA topoisomerase 2α posttranslational modifications and drug
resistance
Christophe Lotz, Valérie Lamour
Cancer Drug Resist 2020;3:149-160 http://dx.doi.org/10.20517/cdr.2019.114
6 Effects of DNA topoisomerase IIα splice variants on acquired drug resistance
Terry S. Elton, Hatice Gulcin Ozer, Jack C. Yalowich
Cancer Drug Resist 2020;3:161-170 http://dx.doi.org/10.20517/cdr.2019.117
